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 Network meta-analysis helps earlier detection of
discriminable effect of antidepressants.
 Guidelines’ infrequent updates failed to capture all
the changes in the evidence.
 Fluctuations in real-world prescriptions could not
be explained by changes in guidelines.
 Marketing efforts might have played a critical role
in prescriptions of antidepressants.1. Introduction
Evidence-based medicine (EBM) provides the principle
for decision-making in medical practice [1]. Ideally, sys-
tematic reviews (SRs) synthesize evidence from clinical tri-
als. Clinical practice guidelines (CPGs) then interpret the
evidence and make concrete recommendations. Eventually,
physicians should update their knowledge with new evidence
and guidelines and share the information with patients so
that they can discuss and agree on a final decision [2].
However, previous studies have revealed potential
problems in this ideal EBM process. Evidence itself
may be biased because of unpublished data [3]. SRs
may be out-of-date at the time of publication [4,5]. Simi-
larly, CPGs may not be updated in a timely manner [6], or
fail to reflect valid evidence because of methodological
flaws [7,8]. When it comes to clinical decision-making,
physicians may not follow the recommendations or evi-
dence because of personal experiences and beliefs, or they
are too busy to access the updated knowledge [9e11].
Further aggravating the problem, both physicians and pa-
tients can be influenced by the pharmaceutical industry’s
marketing strategies [12,13].
Major depressive disorder (MDD) is one of the most
common mental disorders across cultures [14,15]. Antide-
pressants have long been recommended as the first-line
treatment for MDD, although their absolute effectiveness
has been debated to date [16]. Selecting the optimal medi-
cation from an overwhelming array of options is not
straightforward. Earlier evidence based on randomized
controlled trials (RCTs) and pairwise meta-analyses
(MAs) suggested that antidepressants had indistinguishable
efficacy. With the advent of new evidence synthesis
methods, some antidepressants emerged as being more effi-
cacious and acceptable than others [17, 18]. The new body
of evidence comprised a large amount of unpublished data
to minimize publication bias and was synthesized by
network meta-analyses (NMAs), a method that compares
multiple treatments simultaneously. NMA can detect the
difference between treatments earlier and with greaterpower than conventional pairwise MAs [19], hence provide
the highest level of evidence [20, 21].
It remains unclear in the past decades whether CPG rec-
ommendations duly reflected the evidence and how the
real-world prescriptions followed the evidence and CPGs.
The aim of this study is to compare the three elements in this
process, namely synthesized evidence, CPG recommenda-
tions, and real-world prescriptions, for new generation anti-
depressants in treating acute phase MDD through the past
3 decades (Fig. 1). As some of the evidencewas not available
in early years (e.g., unpublished trial reports could not be
retrieved from regulatory agencies until 2000), it was impos-
sible to identify evidence as was available in those days, pre-
sumably in a deficient and biased manner. Rather, we have
shown the evolution of evidence via a series of consecutively
conducted NMAs using the largest network of RCTs to date
[18,22]. Therefore, we use this ideally synthesized evidence
as the benchmark to reveal what should have been in the
CPGs had we been able to perform the best evidence synthe-
sis, which could indicate advantages of implementing NMA.
We have also described real-world prescription patterns of
antidepressants in the past 20 years in the United States,
based on a population representative database [23]. In the
present study, we selected several internationally representa-
tiveCPGs for the pharmacological treatment ofMDD, exam-
ined how they were developed and updated, and extracted
their recommendations. We then compared the ideal evi-
dence based on cumulative NMAs, the CPG recommenda-
tions, and the prescriptions. We described the discrepancies
over time if therewere any and investigated some factors that
may have caused the deviations. Understanding potential
barriers in the process of practicingEBMwill help us identify
future direction of improvement.2. Methods
The protocol for this study has been published [24]. This
study did not require approval by an institutional review
board because only group-level data and deidentified data
were used. It was registered at UMIN Clinical Trials Reg-
istry (identifier: UMIN000031898).
2.1. Three elements of the EBM process
We have previously published and described the first and
the third elements in the EBM process (Fig. 1) [22, 23].
Here, we provide brief summaries of the methods for these
two elements and describe the second element.
2.1.1. Evidence based on cumulative network meta-
analyses
The evidence synthesized in this study was supposed
to reflect the ideal evidence which should have been
available at each retrospective time point. Briefly, the
data set included published and unpublished double-
Fig. 1. Three elements of the evidence-based medicine process and their relationship evaluated in the present study. Rectangles indicate the three
elements studied: a) cumulative evidence about drug effects, b) clinical practice guidelines, and c) prescription patterns. Bubbles indicate impor-
tant factors which may influence the process, but we do not have accurate and sufficient data. Blue bubbles indicate factors we explored, although
indirectly: we studied the impact of patent expiry year and safety warnings from the regulatory agency and compared the share of drugs marketed by
the same company. Factors in gray bubbles are unobserved in this study. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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for adult patients (18 years old) with acute phase
MDD [18]. The primary outcomes were as follows: ef-
ficacy (response rate, measured as the proportion of pa-
tients who achieved a reduction of at least 50% on any
validated depression severity scales compared with base-
line at 8 weeks) and acceptability (all-cause discontinua-
tion rate, measured as the proportion of patients who
withdrew early due to any reasons) [25]. We included only
head-to-head trials (n 5 190) in the present study because
having a placebo arm among the comparisons changed the
nature of the trials [26,27].
To track the evidence evolution, we conducted a series
of cumulative NMAs every 5 years since 1990 (i.e., at
1990, 1995, 2000, 2005, 2010, and 2016, respectively),
each of which included all the RCTs completed up to 1 year
before that date. For each NMA, a random-effects model
was used to estimate the odds ratios (ORs) for both efficacy
and acceptability. Then we assessed the confidence in the
evidence using the CINeMA (Confidence in Network
Meta-Analysis) framework [28, 29], rating the evidence
for each estimate at four levels: high, moderate, low, and
very low confidence (details of assessment are described
in Appendix 1 (p.3-4)). We presented the results in a two-
dimensional plot at each time point. Each node represented
an antidepressant, with x-axis indicating the efficacy while
y-axis indicating the acceptability compared with citalo-
pram, a drug that was consistently prescribed through the
decades. We use a pie chart for each node to illustrate the
level of confidence in the evidence for each drug. Further in-
formation is provided in the study by Luo et al.[22].
2.1.2. Guideline recommendations in the internationally
representative CPGs
As described in the protocol, we have identified all the
published versions of the following English written,representative CPGs concerning the acute phase pharmaco-
logical treatment for adult patients diagnosed with MDD
proposed by these professional institutions (government
agencies or professional academic societies): (1) American
Psychiatric Association (APA) [30e32]; (2) Agency for
Health Care Policy and Research (AHCPR) [33]; (3) British
Association for Psychopharmacology (BAP) [34e37]; (4)
National Institute for Health and Care Excellence (NICE)
[38,39].
Two researchers (Y.L. and E.G.O.) independently ex-
tracted the information about the methodology of guideline
development: (1) search strategies; (2) types of publication
primarily used to produce recommendations; (3) the latest
SRs referenced; (4) whether the panel conducted addi-
tional evidence synthesis and the method of synthesis.
We also extracted specific recommendations. We consid-
ered a drug being recommended if the statement used
‘recommend’, ‘must’, ‘necessary’, ‘should’, ‘appropriate’,
or other similar words to express instructions. Merely
mentioned in the explanatory paragraph without explicit
suggestions was not considered a recommendation. If
the recommendation was in terms of drug category, we
searched the definition in that guideline to identify corre-
sponding drugs. Recommendations regarding particular
subgroups such as elderly, severe, hospitalized, or preg-
nant patients were excluded.
2.1.3. Antidepressant prescriptions in the United States
based on a population-representative database
The real-world prescription patterns were depicted
based on the Medical Expenditure Panel Survey (MEPS)
database in the United States [40]. Briefly, the MEPS com-
prises yearly large-scale surveys since 1996. A total of
20,000 to 40,000 participants from a nationally representa-
tive sample of families and individuals and their medical
providers were involved every year. We included patients
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order and psychotic depression. Our target medications
were antidepressants being approved for MDD by the
US Food and Drug Administration (FDA). We focused
on antidepressant monotherapy, defined as patients who
were prescribed only one antidepressant within the
whole year.
To be consistent with evidence synthesis, the propor-
tion of a particular antidepressant was estimated by the
number of patients with MDD being prescribed that anti-
depressant monotherapy among all the patients with MDD
on monotherapy in the years 1996, 2000, 2005, 2010, and
2015. The calculation was based on the national estimates
using sampling weights. We drew a plot to show the pre-
scription proportions for each antidepressant over the
years. Further details are available in the study by Luo
et al.[23].2.2. Comparison between cumulative NMAs, CPGs, and
real-world prescriptions
First, we compared the ideal evidence based on cumula-
tive NMAs and CPG recommendations. We marked on the
plot of each NMA the drugs recommended by CPGs pub-
lished within 5 years of that NMA, to visually examine
the relative effect indicated by evidence behind the drugs.
We used distinct colors to label drugs that were commonly
recommended by more than two CPGs and those only rec-
ommended by a specific CPG.
Second, we compared CPGs and prescriptions in the
United States. We first examined whether frequently pre-
scribed antidepressants were recommended by CPGs and
whether the time of recommendation matched the growth
in prescription. Conversely, we examined the prescription
proportions for drugs that were recommended by CPGs.
Then, as we anticipated many potential factors might influ-
ence real-world prescriptions (Fig. 1), we investigated the
following: (1) changes in relative efficacy and acceptability
based on NMAs; (2) patent expiry; (3) FDA safety warn-
ings; (4) marketing promotions. For (1), we identified visu-
ally noticeable rises and falls in the prescription trend and
checked whether they were accompanied by apparent
changes in the effect indicated by NMAs. (2) ~ (4) were
examined graphically on the prescription plot. We marked
the year of patent expiry. We searched for FDA safety
warnings on critical side effects after approval for specific
antidepressants. Warnings concerning all antidepressants
(e.g., the black-box warning of suicidal risk) or only to spe-
cific patient groups (e.g., pregnancy use) were excluded.
We tagged the year of warning on the plot. Because we
did not have precise data on marketing investment, we
explored relationship of the market share between drugs
from the same company. We matched the antidepressants
by the company that marketed the branded products to visu-
alize their relations.3. Results
3.1. CPG recommendations
3.1.1. Update frequency
The update of all the guidelines took more than 5 years,
ranging from 5 to 10 years, with a median interval of 7 years
(Table 1).3.1.2. Methodology used in developing CPGs
Most CPGs reported the methodology with details.
Improvement was observed over time: databases searched
were increasing, and new evidence synthesis methods such
as NMAs were adopted gradually. Although all CPGs con-
ducted extensive literature searches on main medical data-
bases, NICE’s was the most comprehensive, including trial
registries and unpublished data. All the CPGs based their
recommendations primarily on published SRs and RCTs.
The newest SRs referenced in the guidelines were usually
published a year before or even in the same year as the pub-
lication of guideline. Pairwise MAs were the most frequent
sources of evidence, except for NICE-2009, BAP-2015, and
NICE-2018, in which NMAs were taken into consideration.
BAP considered the indirect comparisons in NMAs pro-
duced weaker evidence, whereas NICE fully addressed
the interpretations of referenced NMAs. AHCPR and NICE
also conducted MAs and/or NMAs on their own. BAP-2008
and BAP-2015 also referenced previously published
guidelines.3.1.3. Recommendations
We summarized the recommendations in Table 1. Anti-
depressants were recommended as the first-line treatment
for patients with MDD above threshold severity, especially
with persistent symptoms, in all CPGs. Most CPGs claimed
they prioritized drugs with better safety profiles, as most
antidepressants had comparable efficacy. All the CPGs rec-
ommended some particular antidepressants, usually with
unspecified or weaker strength of evidence than the general
statements. Selective serotonin reuptake inhibitors (SSRIs)
were recommended by all the CPGs, although always as a
drug category.
3.2. Comparison between cumulative NMA and CPG
recommendations
As an illustration, Figure 2A compares the NMA as of
2000 with the recommendations in CPGs published be-
tween 2000 and 2005, whereas Figure 2B compares the
NMA as of 2005 with CPGs published between 2005
and 2010 (details in the legend). Most of the commonly
recommended drugs had slightly to moderately better ef-
ficacy than citalopram except fluvoxamine (ORs of
response rate except fluvoxamine: 1.00e1.55 in 2000,
1.00e1.26 in 2005; ORs 1 favor the drug other than cit-
alopram) and comparable or slightly worse acceptability




TCAs SSRIs SNRIs Others
1993 AHCPR US Secondary TCA:
nortriptyline,
desipramine
SSRIs: fluoxetine, paroxetine, sertraline - Trazodone Bupropion
1993 APA US Acceptable SSRIs: fluoxetine, paroxetine, sertraline - Trazodone Bupropion
1993 BAP UK Lofepramine SSRIs: fluoxetine, fluvoxamine,
paroxetine, sertraline
- Trazodone mianserin








































Abbreviations: APA, American Psychiatric Association; NICE, National Institute for Health and Care Excellence; BAP, British Association for
Psychopharmacology; AHCPR, Agency for Health Care Policy and Research. TCA, tricyclic antidepressant; SSRI, serotonin reuptake inhibitor;
SNRI, serotonin and norepinephrine reuptake inhibitor.
a Drug categories are based on National Drug Code Directory of the US Food and Drug Administration. If recommendations were in the form of
drug category rather than a particular drug, all the drugs belonging to that category in accordance with that guideline’s definition are presented.
b NICE-2004 stated that venlafaxine was not appropriate in primary care because of safety concerns. In addition NICE-2009 stated that both
venlafaxine and duloxetine might not be considered as an initial treatment because of safety issues.
c BAP-2015 did not recommend mirtazapine explicitly in the main statements, but suggested it could be considered because of efficacy. The
reason why it was not in the main recommendations was that the evidence for mirtazapine came from indirect comparisons in a network meta-
analysis, which was considered less strong than direct comparisons.
d NICE started the update in 2015, but now it is still ongoing and the formal update has not yet published. The newest draft was updated in May
2018 and was open online (https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0725/documents, https://www.nice.org.uk/guidance/gid-
cgwave0725/documents/full-guideline-updated).
18 Y. Luo et al. / Journal of Clinical Epidemiology 133 (2021) 14e23than citalopram except duloxetine (ORs of discontinua-
tion rate 0.98e1.41 in 2000, 1.08e1.34 except duloxe-
tine in 2005; ORs 1 favor citalopram). Compared
with other SSRIs, fluvoxamine was less favorable in effi-
cacy (OR 0.92 in 2000 and 0.94 in 2005), acceptability
(OR 1.37 in 2000 and 1.34 in 2005), and evidence cred-
ibility (moderate or high confidence accounted for only
3.8% in 2000 and 15.6% in 2005). It was still commonly
recommended by CPGs as one of SSRIs, and no attempt
was made to distinguish between individual SSRIs. Du-
loxetine, despite the low acceptability estimated in2005 in NMA (OR 2.02), was recommended by both
APA and BAP, whereas NICE was against its use as an
initial treatment because of concerns about tolerability.
Bupropion was recommended only by APA because it
was not approved to treat MDD in the UK. In 2000, three
relatively new drugs, nefazodone, reboxetine, and mirta-
zapine were recommended only by BAP. In 2008, BAP
stopped recommending nefazodone and reboxetine,
which is justified by our NMA, as in 2005 both presented
low acceptability and low certainty in the evidence. In
addition, unlike the positive attitude toward venlafaxine
Fig. 2. Comparison between network meta-analyses and guideline recommendations in 2000 (A) and 2005 (B). Results are presented as ORs
compared with citalopram. Efficacy is shown in x-axis, with ORs 1 favoring the specific drug, whereas acceptability is shown in y-axis, with
ORs 1 favoring citalopram. Therefore, the drugs in the right upper corner should be better in both efficacy and acceptability. The node for each
drug is shown in terms of a pie chart, which indicates the composition of 4-level confidence of evidence among all comparisons with that drug, for
both efficacy and acceptability. Green: high, blue: moderate, yellow: low, and red: very low confidence. The size of each node is proportionate to the
inverse of the width of confidence interval regarding efficacy. Bigger nodes indicate better precision in efficacy. Drug names labeled in green indi-
cate that they were commonly recommended by more than two guidelines published within 5 years from the time of network meta-analyses. Names
in orange indicate that they were recommended by British Association for Psychopharmacology (BAP) only (BAP-2000, BAP-2008), whereas those
in purple indicate that they were recommended only by American Psychiatric Association (APA) (APA-2000, APA-2010). The + label indicates a
relatively new drug. ORs, odds ratios. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of
this article.)
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venlafaxine should only be initiated and monitored by
mental health specialists because of its increased risk of
intolerability, overdose toxicity, and withdrawal symptoms.
The plots at other time points are provided in eFigure1
in Appendix 2.1 (p.5-8). In general, the relative efficacy,
acceptability, and confidence in the evidence of drugs
changed every 5 years, as new products were launched into
the market. In addition, eFigure 1 again indicates that BAP
was more open to new drugs becauseit recommended ago-
melatine and vortioxetine in 2015 while other contempo-
rary CPGs did not.3.3. Comparison between CPG recommendations and
prescriptions
Figure 3 shows the prescription patterns of eight most
frequently prescribed antidepressants as monotherapy intreating MDD in the United States during the past 20 years.
eFigure 2 in Appendix 2.2 (p.9) shows it for all available
drugs. Because APA is the only CPG proposed by a US orga-
nization with updates, we could only compare the prescrip-
tion patterns with the APA recommendations. All the eight
antidepressants in Figure 3 were recommended by APA.
However, escitalopramwas not formally recommended until
2010, despite high volume prescriptions beginning in 2005.
Conversely, eFigure 2 shows that most recommended drugs
were relatively frequently prescribed, except for mirtaza-
pine, which was prescribed persistently at low levels.
Figure 3 displays the influence of several factors on pre-
scriptions. First, because of infrequent updating of the
guideline, changes in APA recommendations (marked by
drugs being newly recommended) could not explain the
fluctuations in prescription. Second, a reduction in the share
after patent expired can be seen in sertraline, fluoxetine,
paroxetine, venlafaxine, and escitalopram. Third, the FDA
Fig. 3. Prescriptions of the eight most frequently prescribed antidepressants (as monotherapy) for patients with major depression over the years
(proportions). Drugs whose branded products are marketed by the same company are labeled in the same color, one by a solid line and another
by a dotted line. Circles mark the drug and the year when it was first recommended in the APA guideline. Triangles indicate the year of patent
expiry for a specific drug. Crosses label the safety warning issued by FDA, locating the year and the drug. Note that FDA only published the warning
of QT prolongation for citalopram, whereas the Medicines and Healthcare Products Regulatory Agency in the UK issued it for both citalopram and
escitalopram. For all the labels, the color also matches the drug. *Patent expiration of paroxetine (GSK): the patent was expired in 1999 in the EU
and UK, whereas in the United States, it was still protected (until 2006). However, because several generic companies attained abbreviated new
drug application (ANDA) before 2006, legal actions were taken by GSK. In 2003, the US District Court of Illinois ruled that one generic version of
paroxetine did not infringe GSK’s original patent, and then the generic drug was launched in 2003. (Reference: Generic Depression: Can Paxil
Avoid Prozac’s Fate? Journal of Generic Medicines. 2004, 1(2), 181e184.). (For interpretation of the references to color in this figure legend,
the reader is referred to the Web version of this article.)
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to have caused a prescription decrease. However, the risk
of causing QT prolongation followed a fall for both escita-
lopram and citalopram. Finally, it exhibits a shift pattern in
prescription proportions of the drugs whose branded prod-
ucts are marketed by the same company. A reduction in one
drug was accompanied by an increasing tendency for
another. The shift between the citalopram and escitalopram
pair was around 2005, when citalopram just lost its patent.
Citalopram experienced a drop while escitalopram soon
achieved a very large prescription volume when it was quite
new. There is a slight shift in the prescription proportions of
the fluoxetine and duloxetine pair after fluoxetine lost its
patent. The shift between two longstanding drugs sertraline
and venlafaxine was not obvious. It should be mentioned
that venlafaxine was marketed by Wyeth before Pfizer
completed acquisition of Wyeth in 2009. For paroxetine
and bupropion, paroxetine’s share continued to go down af-
ter patent expiry, while bupropion, whose patent has
expired for long, achieved a slight increase in the share,which may be related to the approval of a new once-daily
sustained-release formulation in 2003.
We also explored the relationship between effect
changes in NMAs and prescription fluctuations. We identi-
fied a visually prominent growth in citalopram and duloxe-
tine share between 2005 and 2010 and a loss of share in
fluoxetine and paroxetine after 2000 (Fig. 3). After
comparing NMA at 2005 and 2010, as well as NMA at
2010 and 2016 (eFigure 1), no corresponding leap or drop
in relative efficacy or acceptability was noticed. In fact, du-
loxetine sustained relatively low efficacy (ORs 1.02e1.13)
and acceptability (ORs 1.61e2.02) in both 2005 and 2010.
Moreover, citalopram and escitalopram were frequently
prescribed immediately on entering the market, where evi-
dence had not yet been sufficient.4. Discussion
Cumulative NMAs suggested that the efficacy, accept-
ability, and confidence in the evidence for certain drugs
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decades. CPGs developed by different groups had unique
features: NICE expressed more concerns on safety, whereas
BAP seemed more open to new drugs and committed more
amendments in their updates. CPGs were developed
following a rigorously reported methodology which
improved over time. Even in comparison with ideally syn-
thesized evidence, no obvious inappropriateness was found
in CPG recommendations. However, NMA could have
helped us differentiate the effect of individual drugs earlier
and detect the changes in the effect. Real-world prescrip-
tions were not against CPG recommendations; however,
the fluctuations could not be fully explained by either CPGs
or cumulative NMAs, and many factors may have played a
role.
Although CPGs were developed based on valid method-
ology, using NMA conducted on a comprehensive data set
as benchmark let us see how it may have facilitated EBM
process. First, consistent with previous studies [19, 41],
NMA could have promoted earlier detection of individual
drug difference in effect. SSRIs were recommended as a
group without further distinguishing within the category
by CPGs, whereas our evidence suggested fluvoxamine
was less favorable in efficacy, acceptability, and evidence
certainty compared with other SSRIs. Second, our cumula-
tive NMAs indicate a rapid change in evidence, implying
that CPGs may need to speed up their updates to catch
up with evidence. Recently, living SRs, based on prospec-
tively designed consecutive NMA, were suggested to be
able to shorten the time of SR update [42e44]. It can
further contribute to a living guideline, which updates as
soon as new evidence becomes available, making timely
recommendations possible [45, 46]. Therefore, high-
quality NMAs based on exhaustive data to minimize publi-
cation bias [3], if being used properly, may increase the pre-
cision and update speed of future CPGs.
Similar to previous studies, our study implies that fac-
tors other than CPG recommendations and evidence may
shape the real-world prescription patterns [47]. Marketing
efforts may be especially worthy of note. We observed a
shift in the prescription share between citalopram and esci-
talopram and between fluoxetine and duloxetine, both
shortly after the patent expiry of the older product, which
may be explained by a switch of promotional resources
from the old drug in favor of the novel product marketed
by the same company. Especially duloxetine’s growth was
before formal recommendation, regardless of its compa-
rably unfavorable efficacy and acceptability indicated in
the NMAs and by FDA’s safety warning. This shift pattern
was also observed among paroxetine and bupropion, right
when bupropion’s new formulation was approved in 2003.
Furthermore, the fact that citalopram and escitalopram
achieved large market shares when they were just launched
also implicitly implies a remarkable role of promotions. It
may be dangerous, especially in the United States, where
direct-to-consumer advertising is legal; the influence wason not only physicians but also patients [48, 49]. How
EBM should be properly implemented under the impact
of marketing needs more attention. In addition, we found
that patient values might also play a role. Mirtazapine ap-
peared an example of interplay between side effect profiles
and unique cultural values. It was recommended by APA,
although the prescription volume remained at low level.
This might be due to its side effect of gaining weight and
increasing serum lipid level, which possibly caused more
worries to American physicians and patients than it did in
other countries [50].
There are some limitations in our study. First, we did not
use any statistical tests to evaluate the associations. Statis-
tical tests such as the correlation test need assumptions and
thus may lose clinical relevancy. Because of the descriptive
nature, we could not draw firm conclusions. Second, owing
to difficulties in acquiring truly available evidence in early
years, we used NMAs to illustrate the evidence. It makes
the comparison not straightforward because NMA was not
applicable in the past. However, comparing with this ideal
evidence helps us realize how NMA could have facilitated
evidence synthesis and how our future practice can be
improved. Besides, our NMAs did not reflect long-term
beneficial and harmful effect, which should have been
valued in CPG development. Nevertheless, it could still
be useful for drug selections. Third, because of lack of
some sufficient and precise information in the MEPS data-
base and for factors like marketing investment, the explana-
tions concerning changes in prescription are generating
hypotheses rather than proving associations. In fact, mar-
keting strategies are not always explicit, like interactions
between representatives from companies and clinicians or
advertisements [51, 52]; they can take more implicit forms,
such as via scientific publications [53, 54], which are even
more dangerous while their influence is hard to be quanti-
fied. Future studies, based on richer and more accurate data,
and from other countries worldwide, are warranted to vali-
date those hypotheses.5. Conclusions
To our knowledge, this is the first study to describe and
compare the evolutions of the three main elements in EBM
process: ideally synthesized evidence about treatment ef-
fects, CPGs, and prescriptions simultaneously, with regard
to antidepressants in treating patients with MDD over the
past 3 decades. The findings indicate that there is still good
room for improvement. CPGs appeared to reflect the evi-
dence base, but NMA could have helped us detect distinc-
tions between individual drugs and changes in the effect
earlier. By contrast, the real-world prescription patterns
showed larger fluctuations which were not fully explicable
either in terms of CPG recommendations or cumulative
NMA results. We suggest enhancements should include
accelerating guideline updates, involving advanced
22 Y. Luo et al. / Journal of Clinical Epidemiology 133 (2021) 14e23evidence synthesis methods for guideline development, and
monitoring the impact of marketing on prescriptions.Acknowledgments
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